Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with curatively resected pancreatic cancer~* Age between 18 and 75~* Eastern Cooperative Oncology Group performance score 0 or 1~* Patients with compliance~* Patients with informed consent~Exclusion Criteria:~* Patients refuse to enroll this study~* Patients with concomitant chemoradiation therapy~* Previous chemotherapy~* Pregnant or preparing a pregnancy~* Uncontrolled infection, diabetes, hypertension, ischemic heart disease, myocardial infarction within 6 months~* Enrolled another clinical trial within 30 days~* Patients will be expected to be risk because of enrollment~* Patients without informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 5-FU group (Type: ACTIVE_COMPARATOR): Grades of hENT1 immunostaining are 0 or 1.
- Gemcitabine group (Type: ACTIVE_COMPARATOR): Grade of hENT1 immunostaining is 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).